CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 7,335	$ 6,911
Marketable securities	1,429	1,973
Receivables	5,704	5,965
Inventories	1,283	1,195
Other Assets, Current	1,342	1,116
Total Current Assets	17,093	17,160
Property, plant and equipment	4,985	5,027
Goodwill	6,536	6,538
Other intangible assets	1,026	1,091
Deferred income taxes	1,380	1,371
Marketable securities	1,233	1,775
Other assets	2,581	2,024
Total Assets	34,834	34,986
Current Liabilities:
Short-term debt obligations	381	1,703
Accounts payable	1,976	1,892
Accrued liabilities	5,856	6,489
Deferred income	103	172
Income taxes payable	525	398
Total Current Liabilities	8,841	10,654
Deferred Income	448	468
Income taxes payable	3,084	3,043
Pension and other liabilities	1,509	1,048
Long-term debt	5,635	5,646
Total Liabilities	19,517	20,859
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	221	221
Capital in excess of par value of stock	2,103	2,081
Accumulated other comprehensive loss	(2,644)	(2,762)
Retained earnings	35,109	34,065
Less cost of treasury stock	(19,571)	(19,574)
Total Bristol-Myers Squibb Company Shareholders' Equity	15,218	14,031
Stockholders' Equity Attributable to Noncontrolling Interest	99	96
Total Equity	15,317	14,127
Total Liabilities and Equity	$ 34,834	$ 34,986